These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12422304)

  • 1. Oxaliplatin-related side effects: characteristics and management.
    Cassidy J; Misset JL
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):11-20. PubMed ID: 12422304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
    Wiseman LR; Adkins JC; Plosker GL; Goa KL
    Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of oxaliplatin in the treatment of colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):15-20. PubMed ID: 11204657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oxaliplatin tolerance in the treatment of metastatic colorectal cancers].
    Bugat R
    Bull Cancer; 2001 Aug; 88 Spec No():S45-9. PubMed ID: 11567914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin in practice.
    Misset JL
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety profile of oxaliplatin.
    Extra JM; Marty M; Brienza S; Misset JL
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
    Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
    Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
    Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
    Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
    James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.